Role of PPIs limited for babies with GORD
PROTON-pump inhibitors (PPIs) are not recommended for gastro-oesophageal reflux disease (GORD) in infants, as evidence for their efficacy and safety is lacking, according to researchers.
Authors of a systematic review found that while PPIs seemed to be well tolerated during short-term use, they were more effective than alternatives in reducing GORD symptoms in only one of five studies.
“Physicians should be careful when prescribing PPIs, medications that are not approved for infants and have potential adverse effects, unless there is a documented disease or with careful monitoring,” said the authors from Australia and the Netherlands.
They studied PPI efficacy and safety in children aged 0–18 years, finding in older children and adolescents PPIs were equally effective to alginates or ranitidine, although placebo-controlled trials were lacking.
Professor Geoffrey Davidson, senior gastroenterologist at the Women’s and